In vivo studies in dextran sulfate sodium-induced colitis models demonstrate that CBF@LCP achieves targeted drug release, mitigates inflammation, reprograms macrophage polarization, preserves intestinal barrier integrity, and activates the phosphatidylinositol 3-kinase/AKT signaling pathway. The gene discussed is AKT1; the disease is colitis.